 Connection
Marc Bonaca to Stroke Volume
This is a "connection" page, showing publications Marc Bonaca has written about Stroke Volume.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.074 |
|
|
|
-
Gluckman TJ, Chiu ST, Rider D, Tseng PK, Mudd JO, Remick JD, Granowitz C, Carroll A, Sikirica S, Canonico ME, Hsia J, Bonaca MP. Relationship Between Left Ventricular Ejection Fraction and ICD-10 Codes Among Patients Hospitalized With Heart Failure. Clin Cardiol. 2024 12; 47(12):e70055.
Score: 0.724
-
Zannad F, O'Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Gates D, Ezekowitz JA, Hernandez AF, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Armstrong PW. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet. 2025 Sep 27; 406(10510):1351-1362.
Score: 0.191
-
Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Felker GM, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, She L, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2025 Sep 27; 406(10510):1341-1350.
Score: 0.191
-
Rafei AE, Harrington JA, Tavares CAM, Guimarães PO, Ambrosy AP, Bonaca MP, Sauer AJ, Vardeny O, Canonico ME. Heart failure with preserved ejection fraction therapeutics: in search of the pillars. Heart Fail Rev. 2025 Sep; 30(5):1005-1014.
Score: 0.187
-
Saldarriaga CI, Zannad F, McMullan CJ, Xing A, Gates D, Anstrom KJ, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Reddy YNV, Rosano GMC, Senni M, Udelson J, Voors AA, Butler J. Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial. Eur J Heart Fail. 2025 Aug; 27(8):1426-1435.
Score: 0.184
-
Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, Ezekowitz JA, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Patel M, Ponikowski P, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial. Eur J Heart Fail. 2025 Feb; 27(2):209-218.
Score: 0.180
-
Bonaca MP, Moslehi JJ, Ledermann JA, Michelon E, Wei C, Moran M, Monk BJ, Pujade-Lauraine E. Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both. Oncologist. 2023 10 03; 28(10):e977-e980.
Score: 0.167
-
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation. 2019 05 28; 139(22):2528-2536.
Score: 0.122
-
Harrington JL, Canonico ME, El Rafei A, Solomon SD, Teerlink JR, Vaduganathan M, Zieroth SR, Bonaca MP, Sauer AJ. Nonsteroidal and Steroidal Mineralocorticoid Antagonists: Rationale, Evidence, and Unanswered Questions. JACC Heart Fail. 2025 Oct; 13(10):102637.
Score: 0.048
-
Verma S, Dhingra NK, Bonaca MP, Butler J, Anker SD, Ferreira JP, Filippatos G, Januzzi JL, Lam CSP, Sattar N, Iwata T, Nordaby M, Brueckmann M, Pocock SJ, Packer M. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled. Arterioscler Thromb Vasc Biol. 2023 07; 43(7):1334-1337.
Score: 0.041
-
Butler J, Usman MS, Anstrom KJ, Blaustein RO, Bonaca MP, Ezekowitz JA, Freitas C, Lam CSP, Lewis EF, Lindenfeld J, McMullan CJ, Mentz RJ, O'Connor C, Rosano GMC, Saldarriaga CI, Senni M, Udelson J, Voors AA, Zannad F. Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum. Eur J Heart Fail. 2022 11; 24(11):2029-2036.
Score: 0.039
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|